This is a preview of subscription content, log in via an institution to check access.
Notes
2020 US dollars
Reference
Muresan B, et al. Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting Applied Health Economics and Health Policy : 12 Jul 2021. Available from: URL: https://doi.org/10.1007/s40258-021-00666-0
Rights and permissions
About this article
Cite this article
Bosutinib cost effective versus dasatinib and nilotinib in CML. PharmacoEcon Outcomes News 883, 4 (2021). https://doi.org/10.1007/s40274-021-7875-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7875-9